MCID: CRB138
MIFTS: 48

Core Binding Factor Acute Myeloid Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Core Binding Factor Acute Myeloid Leukemia

MalaCards integrated aliases for Core Binding Factor Acute Myeloid Leukemia:

Name: Core Binding Factor Acute Myeloid Leukemia 26 17 74
Cbf Acute Myeloid Leukemia 26
Core-Binding Factor Aml 26
Cbf-Aml 26

Classifications:



External Ids:

UMLS 74 C3839741

Summaries for Core Binding Factor Acute Myeloid Leukemia

Genetics Home Reference : 26 Core binding factor acute myeloid leukemia (CBF-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and blood cell fragments called platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets.

MalaCards based summary : Core Binding Factor Acute Myeloid Leukemia, also known as cbf acute myeloid leukemia, is related to leukemia and myeloid leukemia. An important gene associated with Core Binding Factor Acute Myeloid Leukemia is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cytarabine and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Core Binding Factor Acute Myeloid Leukemia

Diseases related to Core Binding Factor Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Related Disease Score Top Affiliating Genes
1 leukemia 30.7 CEBPA FLT3 JAK2 KIT NRAS RUNX1
2 myeloid leukemia 30.3 CBFB CEBPA FLT3 HRAS JAK2 KIT
3 sarcoma 30.3 HRAS KIT KRAS WT1
4 leukemia, acute myeloid 28.3 ABCG2 CBFB CEBPA CSF1R CSF3 FLT3
5 acute myeloblastic leukemia with maturation 10.4 FLT3 KIT
6 thymoma, familial 10.4 HRAS KIT
7 sigmoid neoplasm 10.4 HRAS KRAS
8 testicular gonadoblastoma 10.4 KIT WT1
9 apocrine adenoma 10.4 HRAS KRAS
10 subacute myeloid leukemia 10.3 FLT3 JAK2
11 periampullary adenoma 10.3 HRAS KRAS
12 paronychia 10.3 HRAS KRAS
13 8p11 myeloproliferative syndrome 10.3 FLT3 KIT RUNX1
14 bile duct cysts 10.3 HRAS KRAS
15 aggressive digital papillary adenocarcinoma 10.3 HRAS KIT KRAS
16 giant congenital nevus 10.3 HRAS NRAS
17 lung adenoid cystic carcinoma 10.3 HRAS KIT KRAS
18 chronic eosinophilic leukemia 10.3 FLT3 KIT WT1
19 carcinosarcoma 10.2 HRAS KIT KRAS
20 peritoneal benign neoplasm 10.2 KIT WT1
21 benign struma ovarii 10.2 HRAS NRAS
22 acute erythroid leukemia 10.2 CEBPA JAK2
23 conventional fibrosarcoma 10.2 KIT NRAS
24 gastrointestinal system cancer 10.2 HRAS KIT KRAS
25 diffuse peritoneal leiomyomatosis 10.2 KIT WT1
26 uterine inversion 10.2 CSF1R KIT
27 cytogenetically normal acute myeloid leukemia 10.2 CEBPA FLT3 WT1
28 appendix disease 10.2 HRAS KRAS
29 gastrointestinal system disease 10.2 HRAS KIT KRAS
30 malignant conjunctival melanoma 10.2 HRAS NRAS
31 malignant spindle cell melanoma 10.2 KIT NRAS
32 ovarian melanoma 10.2 HRAS KIT NRAS
33 malignant ovarian surface epithelial-stromal neoplasm 10.2 HRAS KRAS WT1
34 ovary epithelial cancer 10.2 HRAS KRAS WT1
35 vulvar melanoma 10.2 HRAS KIT NRAS
36 schimmelpenning-feuerstein-mims syndrome 10.2 HRAS KRAS NRAS
37 malignant skin fibrous histiocytoma 10.2 HRAS KIT NRAS
38 malignant dermis tumor 10.2 HRAS KIT NRAS
39 marcus gunn phenomenon 10.2 HRAS NRAS
40 central nervous system melanocytic neoplasm 10.2 HRAS KIT NRAS
41 acneiform dermatitis 10.2 HRAS KRAS NRAS
42 liver angiosarcoma 10.2 HRAS KRAS NRAS
43 congenital mesoblastic nephroma 10.1 KIT NRAS WT1
44 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.1 CEBPA FLT3 KIT RUNX1
45 nevus, epidermal 10.1 HRAS KRAS NRAS
46 acral lentiginous melanoma 10.1 KIT NRAS
47 hypereosinophilic syndrome, idiopathic 10.1 KIT WT1
48 leukemia, chronic lymphocytic 2 10.1 HRAS KRAS NRAS
49 differentiated thyroid carcinoma 10.1 HRAS KRAS NRAS
50 melanomatosis 10.1 HRAS NRAS WT1

Graphical network of the top 20 diseases related to Core Binding Factor Acute Myeloid Leukemia:



Diseases related to Core Binding Factor Acute Myeloid Leukemia

Symptoms & Phenotypes for Core Binding Factor Acute Myeloid Leukemia

GenomeRNAi Phenotypes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

27 (show top 50) (show all 65)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.81 KRAS
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.81 CBL CEBPA FLT3 KRAS WT1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.81 CBL CEBPA CSF3 NRAS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.81 CBL
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.81 KRAS
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 10.81 FLT3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 10.81 FLT3 CBFB
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.81 FLT3
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.81 KRAS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.81 CBL CEBPA CSF3 NRAS CBFB
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.81 KRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.81 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.81 NRAS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.81 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.81 CSF3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.81 CBL
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 10.81 CEBPA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.81 KRAS
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.81 CBFB
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.81 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 10.81 CEBPA NRAS
22 Decreased viability GR00055-A-2 10.35 HRAS KRAS
23 Decreased viability GR00106-A-0 10.35 KRAS
24 Decreased viability GR00173-A 10.35 FLT3
25 Decreased viability GR00221-A-1 10.35 CSF1R FLT3 HRAS KIT KRAS NRAS
26 Decreased viability GR00221-A-2 10.35 HRAS KRAS
27 Decreased viability GR00221-A-3 10.35 HRAS NRAS
28 Decreased viability GR00221-A-4 10.35 CSF1R FLT3
29 Decreased viability GR00301-A 10.35 KIT KRAS
30 Decreased viability GR00381-A-1 10.35 KRAS
31 Decreased viability GR00402-S-2 10.35 CSF1R FLT3 HRAS KIT KRAS NRAS
32 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.3 CBFB WT1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.3 FLT3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.3 CBFB
35 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.3 FLT3
36 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.3 CBL FLT3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.3 FLT3
38 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.3 CEBPA FLT3
39 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.3 CBFB CBL CEBPA FLT3 WT1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.3 FLT3
41 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.3 CBFB
42 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.3 CBL
43 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.3 CBL
44 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.3 CBL
45 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.3 WT1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.3 FLT3
47 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.3 CBFB
48 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.3 CBFB CBL
49 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10.3 CBL
50 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.3 CBL

MGI Mouse Phenotypes related to Core Binding Factor Acute Myeloid Leukemia:

47 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 ABCG2 CBFB CBL CEBPA CSF1R FLT3
2 hematopoietic system MP:0005397 10.38 ABCG2 CBFB CBL CEBPA CSF1R CSF3
3 endocrine/exocrine gland MP:0005379 10.37 CBFB CBL CEBPA CSF1R FLT3 HRAS
4 homeostasis/metabolism MP:0005376 10.37 ABCG2 CBFB CBL CEBPA CSF1R FLT3
5 growth/size/body region MP:0005378 10.36 CBFB CBL CEBPA CSF1R FLT3 HRAS
6 immune system MP:0005387 10.36 ABCG2 CBFB CBL CEBPA CSF1R CSF3
7 integument MP:0010771 10.31 ABCG2 CBFB CBL CEBPA CSF1R CSF3
8 cardiovascular system MP:0005385 10.29 CBFB CBL CEBPA HRAS KIT KRAS
9 mortality/aging MP:0010768 10.25 CBFB CBL CEBPA CSF1R FLT3 HRAS
10 liver/biliary system MP:0005370 10.2 ABCG2 CBFB CBL CEBPA JAK2 KIT
11 craniofacial MP:0005382 10.18 CBFB CBL CSF1R HRAS KIT KRAS
12 digestive/alimentary MP:0005381 10.11 CBFB CEBPA HRAS KIT KRAS NRAS
13 no phenotypic analysis MP:0003012 10.11 CBFB CEBPA CSF1R FLT3 HRAS KIT
14 neoplasm MP:0002006 10.1 CBFB CEBPA FLT3 HRAS JAK2 KIT
15 normal MP:0002873 10.1 ABCG2 CBFB CEBPA CSF1R HRAS JAK2
16 limbs/digits/tail MP:0005371 10.02 CBFB CBL CSF1R KIT KRAS NRAS
17 renal/urinary system MP:0005367 9.8 ABCG2 CEBPA CSF3 HRAS KIT KRAS
18 reproductive system MP:0005389 9.76 CBL CEBPA CSF1R JAK2 KIT KRAS
19 respiratory system MP:0005388 9.61 CBFB CBL CEBPA HRAS KIT KRAS
20 skeleton MP:0005390 9.36 CBFB CBL CSF1R FLT3 HRAS JAK2

Drugs & Therapeutics for Core Binding Factor Acute Myeloid Leukemia

Drugs for Core Binding Factor Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 147-94-4, 65-46-3 6253
2
Fludarabine Approved Phase 4,Phase 1 75607-67-9, 21679-14-1 30751
3
Vidarabine Approved, Investigational Phase 4,Phase 1 24356-66-9 21704 32326
4 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
5 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
6 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
7 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
8 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
9 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
10
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
11
Dasatinib Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 302962-49-8 3062316
12 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2,Not Applicable
13 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2,Not Applicable
14 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2,Not Applicable
15 Protein Kinase Inhibitors Phase 3,Phase 1,Phase 2,Not Applicable
16
midostaurin Approved, Investigational Phase 2 120685-11-2 9829523 104937
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
18
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
19
Idarubicin Approved Phase 2,Phase 1,Not Applicable 58957-92-9 42890
20
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
21 Staurosporine Experimental Phase 2 62996-74-1
22 Gastrointestinal Agents Phase 2
23 Hormone Antagonists Phase 2
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
25 HIV Protease Inhibitors Phase 2
26 tyrosine Phase 2
27 Antineoplastic Agents, Hormonal Phase 2
28 glucocorticoids Phase 2
29 BB 1101 Phase 2
30
protease inhibitors Phase 2
31 Autonomic Agents Phase 2
32 Peripheral Nervous System Agents Phase 2,Not Applicable
33 Anti-Inflammatory Agents Phase 2
34 Antiemetics Phase 2
35 Hormones Phase 2
36
Busulfan Approved, Investigational Not Applicable 55-98-1 2478
37
Etoposide Approved Not Applicable 33419-42-0 36462
38
Lenograstim Approved, Investigational Not Applicable 135968-09-1
39
Mitoxantrone Approved, Investigational Not Applicable 65271-80-9 4212
40
Sargramostim Approved, Investigational Not Applicable 123774-72-1, 83869-56-1
41
Vitamin C Approved, Nutraceutical Not Applicable 50-81-7 5785 54670067
42 Etoposide phosphate Not Applicable
43 Aclacinomycins Not Applicable
44 Adjuvants, Immunologic Not Applicable
45 Analgesics Not Applicable
46 Antineoplastic Agents, Phytogenic Not Applicable

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
2 Timed-Sequential Induction in CBF-AML Completed NCT00428558 Phase 3 Chemotherapy (DAUNORUBICINE-CYTARABINE);Chemotherapy (DAUNORUBICINE-CYTARABINE)
3 Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) Recruiting NCT02013648 Phase 3 Dasatinib;Cytarabine;Daunorubicin
4 Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Completed NCT00850382 Phase 1, Phase 2 Dasatinib;daunorubicin;Cytarabine
5 Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia Recruiting NCT03686345 Phase 2 Midostaurin
6 Dexamethasone Added to Intensive Chemotherapy in Older Patients With Acute Myeloid Leukemia (AML) Recruiting NCT03609060 Phase 2 Dexamethasone
7 Efficacy and Safety of Chidamide in CBF Leukemia Recruiting NCT03031262 Phase 1, Phase 2 Cytarabine;Chidamide
8 Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT01238211 Phase 2 Cytarabine;Dasatinib;Daunorubicin Hydrochloride
9 Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02971397 Phase 2 Cytarabine;Daunorubicin Hydrochloride
10 Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia Withdrawn NCT02680951 Phase 1 Dasatinib;Fludarabine;Cytarabine;Idarubicin;Intrathecal (IT) cytarabine
11 Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia Recruiting NCT01050036 Not Applicable
12 The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia Recruiting NCT03173612 Not Applicable Dasatinib

Search NIH Clinical Center for Core Binding Factor Acute Myeloid Leukemia

Genetic Tests for Core Binding Factor Acute Myeloid Leukemia

Anatomical Context for Core Binding Factor Acute Myeloid Leukemia

MalaCards organs/tissues related to Core Binding Factor Acute Myeloid Leukemia:

42
Myeloid, Bone, Bone Marrow, Eye

Publications for Core Binding Factor Acute Myeloid Leukemia

Articles related to Core Binding Factor Acute Myeloid Leukemia:

(show top 50) (show all 72)
# Title Authors Year
1
Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia. ( 29705537 )
2018
2
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. ( 29692343 )
2018
3
SNP-array lesions in core binding factor acute myeloid leukemia. ( 29464086 )
2018
4
Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. ( 29500710 )
2018
5
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. ( 29720733 )
2018
6
Detection of KIT mutations in core binding factor acute myeloid leukemia. ( 30112273 )
2018
7
Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). ( 30117318 )
2018
8
D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. ( 28762080 )
2017
9
KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia. ( 28792268 )
2017
10
Genetic abnormalities in core binding factor acute myeloid leukemia. ( 28883285 )
2017
11
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study. ( 28233452 )
2017
12
D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia. ( 28506695 )
2017
13
Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia. ( 29071049 )
2017
14
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. ( 28556489 )
2017
15
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. ( 28494506 )
2017
16
Prognostic importance of c-kit mutations in core binding factor acute myeloid leukemia: A systematic review. ( 27613372 )
2016
17
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. ( 27298396 )
2016
18
Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia. ( 26880987 )
2016
19
Comprehensive mutational profiling of core binding factor acute myeloid leukemia. ( 26980726 )
2016
20
Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia. ( 26771813 )
2016
21
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. ( 26771376 )
2016
22
Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis. ( 27597292 )
2016
23
Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia. ( 26681050 )
2015
24
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission. A French Acute Myeloid leukemia Intergroup trial. ( 25715404 )
2015
25
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. ( 25753065 )
2015
26
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities. ( 26111469 )
2015
27
Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population. ( 25932436 )
2015
28
Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. ( 24972769 )
2014
29
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. ( 25348871 )
2014
30
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML). ( 24844781 )
2014
31
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. ( 25449688 )
2014
32
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. ( 25088818 )
2014
33
Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. ( 24793731 )
2014
34
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. ( 25006122 )
2014
35
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? ( 24319183 )
2013
36
Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. ( 23677335 )
2013
37
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. ( 23321257 )
2013
38
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. ( 23053179 )
2013
39
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. ( 23266036 )
2013
40
Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. ( 23716553 )
2013
41
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. ( 23783394 )
2013
42
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. ( 23646898 )
2013
43
Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. ( 24226631 )
2013
44
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. ( 22886749 )
2012
45
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. ( 22234698 )
2012
46
Impact of residual normal metaphases in core binding factor acute myeloid leukemia. ( 21928314 )
2012
47
Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. ( 22145956 )
2012
48
Core-binding factor acute myeloid leukemia. ( 22032582 )
2011
49
Core binding factor acute myeloid leukemia (CBF-AML) in MAcxico: a single institution experience. ( 21574542 )
2011
50
Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. ( 21715005 )
2011

Variations for Core Binding Factor Acute Myeloid Leukemia

Expression for Core Binding Factor Acute Myeloid Leukemia

Search GEO for disease gene expression data for Core Binding Factor Acute Myeloid Leukemia.

Pathways for Core Binding Factor Acute Myeloid Leukemia

Pathways related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 CBL CSF1R CSF3 FLT3 HRAS JAK2
2
Show member pathways
13.88 CBL CSF1R CSF3 FLT3 HRAS JAK2
3
Show member pathways
13.69 CEBPA CSF1R CSF3 FLT3 HRAS JAK2
4
Show member pathways
13.56 CBL CSF1R FLT3 HRAS JAK2 KIT
5
Show member pathways
13.32 CSF1R CSF3 HRAS JAK2 KIT KRAS
6
Show member pathways
13.32 CEBPA CSF1R CSF3 FLT3 HRAS JAK2
7
Show member pathways
13.26 CBL CSF1R CSF3 FLT3 HRAS JAK2
8
Show member pathways
13.23 CBL CSF1R FLT3 HRAS KIT KRAS
9
Show member pathways
13.08 CSF1R HRAS JAK2 KIT KRAS NRAS
10
Show member pathways
12.95 CBL HRAS JAK2 KIT KRAS NRAS
11
Show member pathways
12.92 CBL HRAS JAK2 KRAS NRAS
12
Show member pathways
12.84 CSF1R CSF3 FLT3 HRAS JAK2 KIT
13
Show member pathways
12.83 CBL HRAS JAK2 KRAS NRAS
14
Show member pathways
12.76 CBL HRAS KIT KRAS NRAS
15 12.75 CSF1R FLT3 HRAS KIT KRAS NRAS
16
Show member pathways
12.72 CBL HRAS JAK2 KRAS NRAS
17
Show member pathways
12.71 CSF1R FLT3 HRAS KIT KRAS NRAS
18
Show member pathways
12.61 CBL JAK2 RUNX2 TLE1
19
Show member pathways
12.61 HRAS JAK2 KRAS NRAS
20
Show member pathways
12.61 CBL HRAS KRAS NRAS
21
Show member pathways
12.6 CBL HRAS KRAS NRAS
22 12.59 CBL CEBPA JAK2 KIT RUNX1
23
Show member pathways
12.53 CBL HRAS KRAS NRAS
24
Show member pathways
12.5 CBL HRAS JAK2 KRAS NRAS
25
Show member pathways
12.49 CBL HRAS KRAS NRAS
26
Show member pathways
12.46 CBL FLT3 HRAS KRAS NRAS
27
Show member pathways
12.45 CBL HRAS KRAS NRAS
28
Show member pathways
12.45 CBL HRAS KRAS NRAS
29
Show member pathways
12.44 HRAS KIT KRAS NRAS
30
Show member pathways
12.43 CBL CEBPA HRAS JAK2
31
Show member pathways
12.41 CBL HRAS KRAS NRAS
32
Show member pathways
12.36 CBL HRAS KRAS NRAS
33
Show member pathways
12.35 CBL CEBPA CSF1R FLT3 HRAS KIT
34 12.33 CBL HRAS KRAS NRAS
35
Show member pathways
12.32 CSF1R CSF3 HRAS JAK2 KRAS NRAS
36
Show member pathways
12.31 CBL HRAS KRAS NRAS
37
Show member pathways
12.27 CBL CSF1R FLT3 HRAS KIT KRAS
38
Show member pathways
12.24 CBL HRAS JAK2 KRAS NRAS
39
Show member pathways
12.23 CSF1R HRAS KRAS NRAS
40 12.22 CBL HRAS JAK2 KRAS
41
Show member pathways
12.21 CBL HRAS JAK2 KIT
42
Show member pathways
12.18 CBL FLT3 HRAS JAK2 KRAS NRAS
43 12.17 CSF1R HRAS KRAS NRAS
44
Show member pathways
12.17 CBL HRAS KRAS NRAS
45 12.13 HRAS JAK2 KRAS NRAS
46
Show member pathways
12.11 HRAS JAK2 KRAS NRAS
47
Show member pathways
12.1 CBL HRAS JAK2 KRAS NRAS
48
Show member pathways
12.1 CBL HRAS JAK2 KRAS
49
Show member pathways
12.08 HRAS JAK2 KRAS NRAS
50
Show member pathways
12.08 CBL HRAS KRAS NRAS

GO Terms for Core Binding Factor Acute Myeloid Leukemia

Cellular components related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.13 CSF1R FLT3 KIT
2 core-binding factor complex GO:0016513 8.62 CBFB RUNX1

Biological processes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.97 CEBPA CSF1R HRAS JAK2 WT1
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 CSF1R FLT3 HRAS KIT
3 positive regulation of cell migration GO:0030335 9.92 CSF1R HRAS JAK2 KIT
4 positive regulation of gene expression GO:0010628 9.91 HRAS KIT KRAS RUNX2 TLE1 WT1
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 CSF3 JAK2 KIT
6 peptidyl-tyrosine phosphorylation GO:0018108 9.85 CSF1R FLT3 JAK2 KIT
7 male gonad development GO:0008584 9.84 CBL KIT WT1
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.83 CSF1R FLT3 KIT
9 protein autophosphorylation GO:0046777 9.83 CSF1R FLT3 JAK2 KIT
10 negative regulation of apoptotic process GO:0043066 9.82 CBL CSF1R WT1
11 MAPK cascade GO:0000165 9.8 FLT3 HRAS JAK2 KIT KRAS NRAS
12 Ras protein signal transduction GO:0007265 9.78 HRAS KRAS NRAS
13 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.77 HRAS KRAS NRAS
14 positive regulation of MAPK cascade GO:0043410 9.76 CSF1R FLT3 HRAS KIT
15 cellular response to cytokine stimulus GO:0071345 9.73 CSF1R CSF3 FLT3
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 CSF1R FLT3 JAK2 KIT
17 positive regulation of actin cytoskeleton reorganization GO:2000251 9.68 CSF3 HRAS
18 macrophage differentiation GO:0030225 9.68 CEBPA CSF1R
19 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.68 CBFB RUNX1
20 regulation of keratinocyte differentiation GO:0045616 9.67 CBFB RUNX1
21 regulation of regulatory T cell differentiation GO:0045589 9.67 CBFB RUNX1
22 interleukin-6-mediated signaling pathway GO:0070102 9.67 CBL JAK2
23 positive regulation of MAP kinase activity GO:0043406 9.67 FLT3 HRAS KIT KRAS
24 mast cell degranulation GO:0043303 9.66 CBL KIT
25 positive regulation of phospholipase C activity GO:0010863 9.65 HRAS KIT
26 regulation of bicellular tight junction assembly GO:2000810 9.65 CBFB RUNX1
27 cell maturation GO:0048469 9.65 CBFB CEBPA RUNX2
28 hemopoiesis GO:0030097 9.65 CSF1R FLT3 KIT RUNX1 RUNX2
29 regulation of B cell receptor signaling pathway GO:0050855 9.64 CBFB RUNX1
30 regulation of myeloid cell differentiation GO:0045637 9.63 CBFB RUNX1
31 granulocyte differentiation GO:0030851 9.63 CEBPA CSF3
32 regulation of cytokine-mediated signaling pathway GO:0001959 9.61 CBFB RUNX1
33 response to isolation stress GO:0035900 9.58 HRAS KRAS
34 myeloid progenitor cell differentiation GO:0002318 9.57 FLT3 KIT
35 positive regulation of cell proliferation GO:0008284 9.56 CSF1R CSF3 FLT3 HRAS JAK2 KIT
36 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.55 CBL CSF3 FLT3 JAK2 KIT
37 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 9.51 CBFB RUNX1
38 positive regulation of CD8-positive, alpha-beta T cell differentiation GO:0043378 9.49 CBFB RUNX1
39 cytokine-mediated signaling pathway GO:0019221 9.23 CBL CEBPA CSF1R CSF3 FLT3 JAK2
40 signal transduction GO:0007165 10.19 CBL CSF1R HRAS JAK2 KIT KRAS
41 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 CBFB CEBPA CSF3 HRAS RUNX1 RUNX2

Molecular functions related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.95 ABCG2 CSF1R FLT3 JAK2 KIT RUNX1
2 protein binding GO:0005515 9.86 ABCG2 CBFB CBL CEBPA CSF1R FLT3
3 DNA-binding transcription factor activity GO:0003700 9.77 CBFB CEBPA RUNX1 RUNX2 WT1
4 transcription regulatory region DNA binding GO:0044212 9.62 CEBPA RUNX1 RUNX2 WT1
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.61 FLT3 JAK2 KIT
6 protein tyrosine kinase activity GO:0004713 9.46 CSF1R FLT3 JAK2 KIT
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 CSF1R FLT3 KIT
8 nucleotide binding GO:0000166 9.1 FLT3 HRAS JAK2 KIT KRAS NRAS

Sources for Core Binding Factor Acute Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....